Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2024 19:30 ET | Source: Biogen Inc.

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood...
October 30, 2024 06:14 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
October 22, 2024 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
October 17, 2023 07:00 ET | Source: AC Immune SA

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
November 10, 2021 11:50 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...
November 04, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of...
October 29, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event

HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease...
November 04, 2019 16:30 ET | Source: Biogen Inc.

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease...
November 17, 2014 08:02 ET | Source: DiamiR Biosciences Corp.

DiamiR Announces Poster Presentation at the Clinical Trials on Alzheimer's Disease 2014

MONMOUTH JUNCTION, NJ--(Marketwired - November 17, 2014) - DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company's...